Covid-19: Gennova gets DCGI nod to start Phase II/IIII trials for its mRNA vaccine


The company submitted the interim clinical data of the Phase I study to the regulatory authority, Central Drugs Standard Control Organisation (CDSCO). The Vaccine Subject Expert Committee (SEC) reviewed the interim Phase I data and found that HGCO19 was safe, tolerable and immunogenic.